#207 – AMA #35: “Anti-Aging” Drugs — NAD+, metformin, & rapamycin
“It’s really hard to know, in my view, how important sirtuins are as longevity factors…If we accept that, then it’s difficult to know [the importance of] activation of sirtuins by NAD as a longevity mechanism.” —Matt Kaeberlein
#204 – Centenarians, metformin, and longevity | Nir Barzilai, M.D.
“If you prevent aging and age-related disease, you’re going to compress morbidity, too.” — Nir Barzilai
#175 – Matt Kaeberlein, Ph.D.: The biology of aging, rapamycin, and other interventions that target the aging process
“I don’t think I will ever understand aging fully. And I don’t think the field will. … But I also believe that we don’t have to understand it fully to be able to have an impact on the biology of aging through interventions.” —Matt Kaeberlein
Rapamycin risks?
The importance of good science and good interpretation
#171 – Steve Austad, Ph.D.: The landscape of longevity science: making sense of caloric restriction, biomarkers of aging, and possible geroprotective molecules
“I never thought [extending the human lifespan] was going to happen because we got better at treating cancer or we got better at preventing heart disease. I always thought it was going to happen because we would develop something … that would fundamentally change the rate of aging. And we haven’t developed that yet. We’ve got a lot of clues and I think we’re getting closer and closer and closer.” —Steve Austad
How long can we live?; suggested listening
Revisiting the podcast archive
Rapamycin: one of my favorite stories; Ryan Lochte’s flip side on missing Olympic redemption
A few things worth checking out: 07-18-2021
#148 – Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the Interventions Testing Program
“I don’t really care what causes aging. What I care about is: What is the process that can postpone all the different aspects of aging?” — Rich Miller
#123 – Joan Mannick, M.D. & Nir Barzilai, M.D.: Rapamycin and metformin—longevity, immune enhancement, and COVID-19
“I think what the mTOR inhibitors are doing is not stopping people from getting infected [with a virus], but if you get infected, there’s a better immune response and your symptoms will be milder.” — Joan Mannick
#118 – Lloyd Klickstein, M.D., Ph.D.: Rapamycin, mTOR inhibition, and the biology of aging
“Our approach is to address serious aging-associated diseases, and if we’re successful, the side effect will be longevity.” — Lloyd Klickstein